Cover Story ______________________________________________________________________________________________________
SWITCH OFF
IMMUNE-MEDIATED KILLING
MP0533 ( tetraspecific T cell engager )
SWITCH ON
BLOOD STEM CELL
MP0621 ( Switch-DARPin )
Switch-DARPins
Continually pushing the boundaries of what ’ s possible means Molecular Partners has been able to apply DARPin therapies to a variety of conditions . As Alex describes : “ One of our greatest innovations , the multi-specific Switch- DARPin candidate MP0621 is the first program of the Molecular Partners ’ Switch-DARPin platform for targeted and conditional immune cell activation . It is designed as a therapeutic drug and next-generation conditioning regimen for hematopoietic stem cell transplantation ( HSCT ) in AML and other conditions with in vitro and in vivo proof of concept established earlier in 2024 .
40